Ditch The VC: Alternative Funding Options For Biotech Startups
Getting money for a biotech startup can be a daunting task. Venture capital is not the only -- and not always the best -- option to fund a life sciences company.
'mega Block' In Amazon's Backyard Will Become A Life Sciences Campus Following $143.5M Deal; Proceeds To Fund Affordable Housing - Geekwire
One of the last big chunks of land in the booming Seattle neighborhood of South Lake Union will turn into a life sciences hub -- with proceeds of the sale helping fund affordable housing and homelessness issues. The City of Seattle announced today that it will sell the so-called Mercer Mega Block to Alexandria Real Estate Equities, a developer of biotech and life sciences spaces.
Kbl Merger Corp. Iv Spac Signs Definitive Business Combination Agreement To Acquire Cannbiorx Life Sciences Corp.
NEW YORK, July 26, 2019 /PRNewswire/ -- KBL Merger Corp. IV (NASDAQ: KBLM) ("KBLM"), a Special Purpose Acquisition Company (SPAC), announced today that it has executed a definitive business combination agreement for the merger of a wholly owned subsidiary of KBLM with CannBioRx Life...
Omega Capital And Oklahoma Life Science Fund Announce Recapitalization Of Careatc, Leader In Employee Population Health Management
Omega Capital and Oklahoma Life Science Fund Announce Recapitalization of CareATC, Leader in Employee Population Health Management TULSA, Okla., June 5, 2019-- Oklahoma-based Omega Capital and the Oklahoma Life Science Fund announce the recent growth recapitalization of CareATC, Inc. by LLR Partners, a middle market private equity firm in Philadelphia. Terms of the transaction were not disclosed. Tulsa-based CareATC, Inc. is a technology-driven employee population health management company founded by Ron Woods in 2000. Omega Capital and the Oklahoma Life Science Fund provided the company's first institutional capital in 2014.
Storm Therapeutics Extends Series A To GBP 30m (usd 38.43m) With New Investor, Seroba Life Sciences
CAMBRIDGE, England, May 20, 2019-- STORM Therapeutics ("STORM"), the drug discovery company tackling disease through modulating RNA modifying enzymes, today announced that it has raised an additional PS14 million bringing the total Series A financing to PS30 million. The financing includes funding from new investor, Seroba Life Sciences ("Seroba"). STORM's existing investors, Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group also participated in the fundraise. This extension follows the company's rapid progress to date.
Sirnaomics In Raises $22M Led By Hong Kong's Cr-cp Life Sciences Fund
Other investors joining the round are Shanghai-based Rich Yield Capital, Rolling Boulder Investment from Shenzhen and US-based Legend Sky Investment. The post Sirnaomics In raises $22m led by Hong Kong's CR-CP Life Sciences Fund appeared first on DealStreetAsia.
Here's How Early-stage Investors See The Northwest's Life Science Market - Geekwire
Hey investors, how does the Pacific Northwest stack up in life sciences? It's a loaded question, given that venture capitalists invested far less in the Pacific Northwest in 2018 than leading regions in terms of total investment, number of deals and deal size. The average deal size in San Francisco and New England last year was around $60 million, double the roughly $30 million average that Northwest companies saw, according to data presented by Karen Bernstein, co-founder of BioCentury, at the 2019 Life Science Innovation Northwest conference in Seattle earlier this week.
Xconomy: Hatteras Launches New Fund With $94M For Life Science Investments
Hatteras Venture Partners is kicking off its latest fund with $94 million it plans to deploy to life sciences startups. The cash committed so far is the first closing of a fund that Hatteras says could reach up to $200 million. It's the sixth fund for Durham, NC-based Hatteras. The venture capital firm invests throughout [...]
Xconomy: San Diego Life Sciences Roundup: Evofem, Cullgen, Brainleap & More
Locally based biotech companies receive fresh funding from investors. A software startup launches games that it says may help children with disorders that cause attention difficulties. Get the details on these developments and more in San Diego life sciences news: --Evofem Biosciences (NASDAQ: EVFM) struck a deal to raise up to $80 million in a [...]
Blackstone Life Sciences And Novartis To Launch Cardiovascular Drug Company
The life sciences business of Manhattan-based Blackstone Group is making its first investment, spending $250 million to form a company with drugmaker Novartis, called Anthos Therapeutics, that will... To view the full story, click the title link.